Program timeline · status 11 Oct 2029Illustrative end-state sample — forward-dated, not reconciled
Gate 0
Mar 2022
Go
Stage 1
Nonclinical
Gate 1
Dec 2022
Go
Stage 2
IND & Phase 1
Gate 2
Jun 2023
Go
Gate 3
May 2024
Go
Gate 4
Jun 2026
Go w/ conditions
Stage 4
Phase 3
You are here
Gate 5
Sep 2028
Gate 6
Oct 2029
Launch
Nov 2029
Vitalis Therapeutics Inc. — The recorded decision of the Development Committee at Gate 6, the approval and launch gate for VitaFlow (VTX-401), held 2029-10-11. Outcome GO (5-0). Covers launch readiness against eight criteria, the label as granted, post-marketing obligations, and the forecast the Committee refused to launch against.
GO (5-0)
Outcome
7 / 8
Readiness criteria met
None
Tranche released
4
Post-marketing obligations
Contents
Forward-dated end-state sample. This record speaks from 2029-10-11, the target
action date — three years beyond the 15 October 2026 status date of the in-flight
suite, and deliberately not reconciled against it.
1. Decision
| Gate | Gate 6 — Approval & Launch |
| Held | 2029-10-11 |
| Outcome | GO (5-0) |
| Approval received | 2029-10-05 — six days ahead of the action date |
| Action date met | yes |
| Tranche released | None. Gate 6 releases no funding. |
| First commercial shipment | 2029-11-01 |
Gate 6 does not decide whether the drug is approved. The agency decided that on
2029-10-05, and the Development Committee has no standing to review, ratify or reconsider
it. Approval is an input to this gate.
Gate 6 decides whether to launch — whether supply, safety systems, field force, pricing and access are ready to put an approved product into patients' hands. That is a genuinely different question, and unlike approval it is one the sponsor controls.
A program can be approved and not ready to sell. Confusing the two is how launches happen before the organization behind them is capable of supporting one.
Gate 6 decides whether to launch — whether supply, safety systems, field force, pricing and access are ready to put an approved product into patients' hands. That is a genuinely different question, and unlike approval it is one the sponsor controls.
A program can be approved and not ready to sell. Confusing the two is how launches happen before the organization behind them is capable of supporting one.
2. Launch Readiness
| Criterion | Status | Evidence |
|---|---|---|
| Approval received | met | 2029-10-05, six days ahead of the action date. An input to this gate, not a criterion the Committee assessed. |
| Commercial supply released and in the distribution network | met | Launch quantity manufactured, released against qualified methods, and positioned at wholesaler depots under validated cold chain. |
| Manufacturing capacity confirmed for the first 12 months | met | Aldergate capacity reserved. Second-source qualification is a Year 2 activity. |
| Pharmacovigilance system operational for a marketed product | met | Post-marketing safety reporting differs from IND reporting; the system was rebuilt for it, not carried over. |
| Field force hired, trained and deployed | met | Trained on the approved label — not the sought label. |
| Payer coverage secured at plan | not met | 44% of covered lives against a 62% assumption. The consequence of GC-03 closing late, arriving exactly where it was predicted to. |
| Pricing approved | met | Net price set at $11,050 against the $12,500 the Gate 4 business case carried. |
| Post-marketing obligations accepted and owned | met | Assigned to permanent functions, not to the program. |
Seven of eight met. The one that did not is the one this whole suite has been pointing at.
Payer coverage came in at 44% of covered lives against a 62% assumption. That is not a surprise, an accident, or a market development nobody foresaw. It is the arrival of GC-03 — the market access evidence condition issued at Gate 4 in June 2026, flagged at risk at the October 2026 status date, and closed late in mid-2027.
The advisory boards were eventually held. The evidence was eventually assembled. But it was assembled after the pricing and access strategy had been built on assumptions it was supposed to test — and by then the strategy was hard to change. The condition did not prevent the outcome. It ensured nobody could claim the outcome was unforeseen.
Payer coverage came in at 44% of covered lives against a 62% assumption. That is not a surprise, an accident, or a market development nobody foresaw. It is the arrival of GC-03 — the market access evidence condition issued at Gate 4 in June 2026, flagged at risk at the October 2026 status date, and closed late in mid-2027.
The advisory boards were eventually held. The evidence was eventually assembled. But it was assembled after the pricing and access strategy had been built on assumptions it was supposed to test — and by then the strategy was hard to change. The condition did not prevent the outcome. It ensured nobody could claim the outcome was unforeseen.
Alternatives Considered
A decision record that shows only the decision has recorded an outcome, not a decision. Four options were on the table with a known unmet readiness criterion.
| Option | Case for | Case against | |
|---|---|---|---|
| Launch as authorized | Selected | Accepts a 44% coverage position and begins building real-world evidence immediately. | Revenue below plan in the opening window; the position improves only through subsequent contracting cycles. |
| Defer launch one quarter | Rejected | Would allow one further formulary cycle before first shipment. | Formulary cycles run on payers' calendars, not the sponsor's. A quarter's delay consumes patent life without accelerating a single coverage decision. |
| Limited launch — high-access regions only | Rejected | Concentrate field effort where coverage is strongest. | Signals low confidence to payers in the deferred regions and complicates a later national launch. Also forfeits early real-world evidence from the broader population. |
| Delay to renegotiate price | Rejected | Accept a lower net price in exchange for preferred placement. | The price was already at $11,050. Further concession without a differentiating claim sets a floor the product never recovers from. |
The second option is the one a reader will ask about, and the reasoning against it is the most
useful sentence in this record.
Formulary cycles run on payers' calendars, not the sponsor's. Deferring launch by a quarter does not accelerate a single coverage decision — it simply means the product is unavailable during a quarter in which the coverage position would have improved by exactly as much either way. The delay costs patent life and buys nothing.
That is a genuinely counter-intuitive result. The instinct with an unmet access criterion is to wait until it is met. Here, waiting does not make it met; it makes it met later, with less commercial life remaining to exploit it.
Formulary cycles run on payers' calendars, not the sponsor's. Deferring launch by a quarter does not accelerate a single coverage decision — it simply means the product is unavailable during a quarter in which the coverage position would have improved by exactly as much either way. The delay costs patent life and buys nothing.
That is a genuinely counter-intuitive result. The instinct with an unmet access criterion is to wait until it is met. Here, waiting does not make it met; it makes it met later, with less commercial life remaining to exploit it.
The fourth option deserves note for a different reason. Conceding further price to buy preferred placement is always available and always tempting, and the Committee rejected it on a structural ground rather than a financial one: a price concession made without a differentiating claim sets a floor the product never recovers from. Net price was already at $11,050 against a $12,500 assumption. Every subsequent contract would have negotiated from the lower number.
3. The Label as Granted
- Class boxed warning for thyroid C-cell tumors carried, as planned (D-07).
- No REMS required — the position held.
- Indication granted for BMI ≥30, or ≥27 with at least one comorbidity — the full population sought.
- Tolerability language in Section 6 is descriptive. No comparative tolerability claim was granted, which is the commercially significant outcome.
| Sought | Granted | Assessment |
|---|---|---|
| Indication: BMI ≥30, or ≥27 with a comorbidity | Granted in full | the whole population sought |
| No REMS | No REMS | the position held |
| Class boxed warning carried | Carried | planned for since D-07 |
| Comparative tolerability claim | Not granted | the commercial thesis |
The label is broad and undifferentiated, and those two facts pull against each other.
Getting the full sought population is a genuinely good outcome — a narrowed indication would
have cut the addressable market directly. But the product enters a class of approved alternatives
with nothing in Section 6 that distinguishes it from them.
A broad label with no differentiating claim means the product competes on access and price rather than on evidence. Which is precisely the competition the 44% coverage position made hardest to win.
A broad label with no differentiating claim means the product competes on access and price rather than on evidence. Which is precisely the competition the 44% coverage position made hardest to win.
4. Post-Marketing Obligations
| Ref | Type | Obligation | Note |
|---|---|---|---|
| PMR-1 | Required | Pediatric study, ages 12–17 | The PREA deferral. Final report due 2034. Also the route to pediatric exclusivity. |
| PMR-2 | Required | Long-term cardiovascular outcomes follow-up | Extension of the CR-02 sub-study cohort. Final report due 2035. |
| PMC-1 | Commitment | Pregnancy exposure registry | Agreed with the agency. Not compelled by statute, but a commitment on the record. |
| PMC-2 | Commitment | Ongoing stability on one commercial batch per year | The standing obligation from the stability program. |
PMR and PMC are not the same thing. A post-marketing requirement is compelled
— by statute, by PREA, or as a condition of approval — and failure to meet it carries
regulatory consequence. A post-marketing commitment is agreed rather than compelled, but it
sits on the record and the agency will ask about it.
Conflating them is common and expensive: a program that treats a PMR as a commitment will under-resource it, and one that treats every commitment as compelled will over-resource work it could have negotiated.
Conflating them is common and expensive: a program that treats a PMR as a commitment will under-resource it, and one that treats every commitment as compelled will over-resource work it could have negotiated.
Every one of these outlives the program, and that is the point of recording them at a gate.
PMR-1 reports in 2034. PMR-2 in 2035. The ongoing stability commitment has no end date at all.
The program that created these obligations closes in June 2030. So the gate assigns each to a permanent function rather than to a program role — and the Post-Launch Review and closure report exist partly to make that handover explicit. An obligation owned by an organizational unit that is about to be dissolved is an obligation nobody owns.
The program that created these obligations closes in June 2030. So the gate assigns each to a permanent function rather than to a program role — and the Post-Launch Review and closure report exist partly to make that handover explicit. An obligation owned by an organizational unit that is about to be dissolved is an obligation nobody owns.
5. The Forecast the Committee Refused to Launch Against
Before authorizing launch, the Committee required the Year 1 revenue forecast to be rebuilt.
| Amount | |
|---|---|
| Original Year 1 forecast | $152,000,000 |
| Rebuilt Year 1 forecast | $118,000,000 |
| Reduction | 22% |
The Committee accepted a rebuilt Year 1 forecast before authorizing launch, rather than launching against a number it knew to be stale.
This is the CFO's Gate 4 abstention finally discharged, four years later.
M. Thornbury abstained at Gate 4 rather than voting against, on the specific ground that gross-to-net assumptions had not been refreshed against current payer data. That abstention did not block the gate and was never intended to. What it did was put a question on the permanent record, in a form that could not be quietly resolved by anyone who found it inconvenient.
It surfaced twice more: at Gate 5, where the model was rebuilt at $11,050 and the CFO voted GO; and here, where the Committee refused to authorize a launch against a forecast it knew to be stale.
A single abstention, correctly recorded, did more work over four years than most votes do.
M. Thornbury abstained at Gate 4 rather than voting against, on the specific ground that gross-to-net assumptions had not been refreshed against current payer data. That abstention did not block the gate and was never intended to. What it did was put a question on the permanent record, in a form that could not be quietly resolved by anyone who found it inconvenient.
It surfaced twice more: at Gate 5, where the model was rebuilt at $11,050 and the CFO voted GO; and here, where the Committee refused to authorize a launch against a forecast it knew to be stale.
A single abstention, correctly recorded, did more work over four years than most votes do.
Even the rebuilt figure proved optimistic. The Post-Launch Review reports actual revenue of $91,400,000 against this $118,000,000 plan — a further 22.5% shortfall. Rebuilding a forecast is not the same as getting it right.
6. Why This Gate Releases No Money
Gate 6 authorizes launch and releases nothing. The full $217,000,000 base authorization was released at Gate 5; commercial launch investment sits under a separate authorization that is not this program's to give.
So what is a gate that releases no funding actually for?
Two things. It is the point at which the organization decides to sell the product — a decision that deserves the same evidentiary discipline as a decision to spend, and that would otherwise be taken by default the moment approval arrived. And it is the point at which the program's obligations are formally handed to permanent owners, which is the last thing a program can do while it still exists.
Gate 2 was the other gate that released nothing, for a comparable reason: some decisions matter because of what they commit the organization to, not because of what they fund.
Two things. It is the point at which the organization decides to sell the product — a decision that deserves the same evidentiary discipline as a decision to spend, and that would otherwise be taken by default the moment approval arrived. And it is the point at which the program's obligations are formally handed to permanent owners, which is the last thing a program can do while it still exists.
Gate 2 was the other gate that released nothing, for a comparable reason: some decisions matter because of what they commit the organization to, not because of what they fund.
7. What This Record Establishes
- Approved 2029-10-05, action date met, full indication granted, no REMS.
- Launch authorized GO (5-0) for first shipment 2029-11-01.
- Seven of eight readiness criteria met. The unmet one — payer coverage at 44% against 62% — was the arrival of a risk recorded three years earlier.
- The Committee launched anyway, with the shortfall minuted rather than resolved.
- Four post-marketing obligations assigned to permanent owners, the longest reporting in 2035.
The honest reading of a GO with a known unmet criterion. The Committee could have deferred
launch to improve coverage. It did not, and the reasoning is recorded: coverage improves through
contracting cycles that run on payers' calendars, not the sponsor's, and delaying launch would
have consumed patent life without accelerating a single formulary decision.
That is very likely the right call. It is also the call that produced a 22.5% revenue miss in the first window. Both things are true, and a governance record that recorded only the reasoning and not the outcome would be worth nothing to whoever reads it next.
That is very likely the right call. It is also the call that produced a 22.5% revenue miss in the first window. Both things are true, and a governance record that recorded only the reasoning and not the outcome would be worth nothing to whoever reads it next.